马格诺莉亚Officinalis皮层挥发性油通过双重cAMP介导的途径缓解了喘:抗炎和支气管扩张
Kedi Li1, Zhangjing Cao1, Jiayao Sun1
1State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Journal of ethnopharmacology
|September 19, 2025
概括
马格诺利亚官员植物挥发性油 (MVO) 通过放松呼吸道光滑肌肉和减少炎症,有效治疗喘. 它调节cAMP/PKA/CREB通路,抑制NF-κB并恢复平衡,从而产生双重治疗效果.
科学领域:
- 药理学和中国传统医学
- 呼吸系统医学和免疫学
- 分子生物学和信号转导
背景情况:
- 马格诺利亚 (Magnoliae Officinalis Cortex,MOC) 是一种传统的草药,用于治疗各种疾病,包括胃肠道问题和喘.
- 它的挥发性油 (MVO) 对喘治疗的治疗潜力需要进一步研究.
研究的目的:
- 研究MVO对喘的治疗作用.
- 阐明潜在的分子机制,特别关注cAMP信号通路.
主要方法:
- 结合气体染色学-质谱学 (GC-MS) 与体内 (OVA诱导的喘模型) 和体内 (隔离的气管环) 实验.
- 通过肺功能测试,组织学分析,炎症细胞计数,ELISA和西式涂抹来评估治疗效果.
- 通过使用特定的抑制剂和测量,研究和cAMP信号通路的作用.
主要成果:
- 含有大量的eudesmols和o-cymene.MVO含有大量的eudesmols和o-cymene.
- 在体内,MVO改善了肺功能,减少了呼吸道炎症,粘液产生,Th2细胞因子和IgE水平.
- MVO上调调节了cAMP和p-PKA/p-CREB,抑制了NF-κB的激活,并降低了细胞内水平. 在体外,MVO通过阻断L-VDCC和NSCC/TRPC通道来放松气管滑肌.
结论:
- 通过调节cAMP/PKA/CREB通路,MVO减轻了气道过敏反应,抑制了NF-κB驱动的炎症.
- MVO恢复cAMP/Ca2+稳态,显示出双重的支气管扩张和抗炎作用.
- 这项研究强调了MVO作为一种潜在的喘治疗药物,通过一种新的针对cAMP的策略.
相关概念视频
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Antiasthma Drugs: Methylxanthines
1.6K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K


